FDA expands Eli Lilly’s EBGLYSS dosing schedule, allowing atopic dermatitis patients to receive maintenance shots every eight weeks

Eli Lilly and Company said the U.S. Food and Drug Administration has approved a new maintenance dosing schedule for EBGLYSS (lebrikizumab-lbkz), its targeted biologic for moderate-to-severe atopic dermatitis, commonly known as eczema. Under the FDA’s decision, eligible patients can receive one EBGLYSS injection every eight weeks as maintenance treatment rather than returning to more frequent dosing intervals.

Lilly said the maintenance regimen is a single subcutaneous injection of 250 mg in 2 mL. The therapy is intended for adults and adolescents who are 12 years of age and older and at least 40 kilograms, with moderate-to-severe atopic dermatitis that is not adequately controlled with topical therapies, a description consistent with the product’s earlier FDA labeling and Lilly’s investor materials.

By shifting the maintenance interval to every eight weeks, the new regimen is designed to reduce treatment burden. Coverage summaries of the FDA action indicate the schedule can cut maintenance injections to as few as six per year. That convenience point matters commercially because adherence often becomes harder when patients must receive injections more frequently, particularly in chronic conditions where symptoms can fluctuate and the disease burden extends beyond skin changes.

The FDA’s approval also fits into a broader effort by Lilly to refine how EBGLYSS is used after patients achieve initial control. Lilly has previously emphasized durability of disease control in clinical programs, describing multi-year skin improvement in late-stage studies of lebrikizumab-lbkz. In a March 2026 update carried by PR Newswire, Lilly said EBGLYSS delivered up to four years of durable disease control in a Phase 3b study (ADlong), supporting the idea that the medicine can maintain benefit over extended periods in atopic dermatitis.

EBGLYSS is an IL-13 inhibitor, meaning it targets interleukin-13, a indicating protein involved in eczema inflammation. Lilly has positioned it as a first-line biologic option for patients with moderate-to-severe atopic dermatitis who are not well controlled with topicals. For payers and clinicians, dosing schedules can be as important as efficacy, because they affect drug utilization, administration workflows, and patient retention.

Still, the announcement and secondary coverage do not spell out every practical detail patients and providers will likely ask about, including how quickly patients must switch to the new eight-week maintenance interval, whether prior topical therapy is expected before starting EBGLYSS in all cases, and what specific clinical criteria the FDA used for eligibility on the maintenance schedule. Those points are typically clarified in the full prescribing information, which can include requirements around concomitant therapies and start or stop rules.

Market observers will likely watch whether the eight-week schedule accelerates EBGLYSS uptake by improving the user experience and by lowering the administrative frequency of injections for both patients and care sites. It could also affect competitive positioning among systemic therapies for eczema, where convenience and dosing cadence can influence prescribing decisions.

For now, Lilly’s next steps are likely to include updating sales materials and working with clinicians and payers to incorporate the eight-week maintenance option into treatment pathways. The immediate question for the market is how quickly the new dosing interval translates into real-world adoption and whether it changes expected utilization rates for EBGLYSS compared with prior maintenance schedules.